
A New Shingles Vaccine Posts 91.6% Efficacy in a 26,000-Person Trial
The LZ901 vaccine was 91.6% effective against shingles in a phase 3 trial of 26,018 adults aged 40 and older, published in Nature Communications. Protection was not evenly distributed across age groups: efficacy reached 93.9% in adults aged 40 to 69 but fell to 66.9% in those aged 70 and older. The trial, registered as […]









